OSTOFORM LIMITED

Their core work

Ostoform is an Irish medical device SME developing advanced skin-barrier products for people living with a stoma (ostomy). Their core work combines hydrocolloid materials with non-absorbent compounds to create devices that protect peristomal skin — a persistent clinical problem that causes pain, leakage, and reduced quality of life for ostomy patients. They followed the classic SME Instrument trajectory: a Phase 1 feasibility study in 2018 proved the concept, and a Phase 2 grant of over EUR 1.2M funded the full innovation project through 2021. This progression signals a company building a commercial product, not conducting academic research.

What they specialise in

How they've shifted over time

In their first project (OSTOF, 2018), the emphasis was firmly on the materials themselves — hydrocolloids and non-absorbent compounds — suggesting the early work was about identifying and validating the right material combination. By the follow-on project (OSTOFORM, 2019–2021), the keyword narrows to "ostomy" alone, which is consistent with a shift from material science exploration to integrated device development and clinical or market validation. The trajectory is linear and purposeful: from ingredient to finished product.

Ostoform appears to have completed an EU-funded product development cycle by 2021 and is likely now in commercialisation or market-entry phase — a potential partner for clinical trials, distribution networks, or wound-care platform integrations rather than further basic research.

How they like to work

Ostoform coordinates both of its projects solo, with zero recorded consortium partners — an unusual profile that reflects the SME Instrument model, which is designed for single companies developing their own innovation. They are not consortium builders and show no history of collaborative research with universities or other firms. Anyone approaching them for partnership should expect a company-led relationship where Ostoform drives the agenda, not a co-development dynamic.

Ostoform has no recorded H2020 consortium partners and has collaborated with organisations in zero other countries. Their EU project activity is entirely self-contained, which is typical for SME Instrument awardees but means there is no established European research network to leverage through them.

What sets them apart

Ostoform occupies a very narrow and clinically specific niche — ostomy skin health — where relatively few SMEs operate with dedicated R&D funding at this level. Having secured both phases of the SME Instrument (Phase 1 + Phase 2) for the same technology is a credibility signal: the European Commission's evaluators validated the concept twice. For a consortium needing a specialist in stomal or wound-adjacent medical devices, they are one of the few EU-funded companies with a documented product development track record in this exact area.

Highlights from their portfolio

• OSTOFORM
  The largest grant in their portfolio at EUR 1.285M, this SME Phase 2 award represents a full innovation project and is the clearest signal that Ostoform was developing a market-ready medical device, not just conducting research.
• OSTOF
  The Phase 1 feasibility study that initiated the funding trajectory — notable because winning both SME-1 and SME-2 for the same core technology is uncommon and demonstrates sustained evaluator confidence.